Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Journal of the National Cancer Institute
New model predicts relapse in early breast cancer patients following endocrine therapy
October 9th, 2008
Researchers have developed and validated a model that predicts relapse in women with stage 2 or 3 breast cancer who have been treated with endocrine therapy prior to surgical removal of the tumor, according to a study published online September 23 in the Journal of the National Cancer Institute. The preoperative endocrine prognostic index (PEPI) may help identify women who can safely avoid chemotherapy and those women at high risk of relapse who should be considered for aggressive therapy. Oncologists increasingly treat women with stage 2 and 3 estrogen receptor (ER)-positive breast cancer with endocrine therapy, such as tamoxifen or letrozole, prior to surgery to...
Source: Women's Health Weekly (2008-10-09)
|
